digoxin
TRANSCRIPT
![Page 1: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/1.jpg)
Powerpoint Templates Page 1Powerpoint Templates
Case Presentation
Dr.Yassin
![Page 2: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/2.jpg)
Powerpoint Templates Page 2
History
• 2 years old healthy boy.
• Presented with Hx of ingestion of digoxin tablets . 15 min prior to ER visit.
• Amount is unknown.
• Digioxin 62.5 mic .
![Page 3: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/3.jpg)
Powerpoint Templates Page 3
History
• No Hx of abnormal movement.
• No Hx of vomiting.
• No Hx of palpitation.
![Page 4: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/4.jpg)
Powerpoint Templates Page 4
History
• Perinatal Hx:
• Past medical and surgical Hx:
• Allergy:
• Vaccination Hx:
• Family Hx:
• Social Hx:
• Developmental Hx:UNREM
ARKABLE
![Page 5: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/5.jpg)
Powerpoint Templates Page 5
EXAM• Looks well.
• HR: 123
• RR: 24
• B/P: 109\47
• Temp: 36.5
• CVS: WNL
• RS: WNL
• CNS: WNL
• ABDOMIN: WNL
![Page 6: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/6.jpg)
Powerpoint Templates Page 6
ER course
• Patient taken immediately to ER.
• Gastric lavage done revealed tablet particles.
• Charcol given.
![Page 7: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/7.jpg)
Powerpoint Templates Page 7
impression
Digoxin ingestion
![Page 8: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/8.jpg)
Powerpoint Templates Page 8
PLAN OF
CARE
investigation treatment education
![Page 9: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/9.jpg)
Powerpoint Templates Page 9
investigation
![Page 10: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/10.jpg)
Powerpoint Templates Page 10
investigation
![Page 11: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/11.jpg)
Powerpoint Templates Page 11
![Page 12: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/12.jpg)
Powerpoint Templates Page 12
investigation
![Page 13: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/13.jpg)
Powerpoint Templates Page 13
investigation
![Page 14: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/14.jpg)
Powerpoint Templates Page 14
Digoxin Toxication
![Page 15: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/15.jpg)
Powerpoint Templates Page 15
digoxin• Antiarrhythmic agent, inotrope.• Cardiac Glycoside.
• T1/2: Premature infants, 61–170 hr.• full-term neonates, 35–45 hr.• infants, 18–25 hr.• children, 35 hr.
• Indication: heart failure, Supraventricular tachycardia .
![Page 16: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/16.jpg)
Powerpoint Templates Page 16
Presentation of toxication
• CVS: asystole, atrial or nodal ectopic beats. • A-V block, AV dissociation, S-A block,
ventricular arrhythmias, • first-, second- (Wenckebach), or third-degree
heart block.• CNS: Seizure.lethargy, headache, visual
disturbance. • electrolyte imbalances Hyperkalemia • GIT: diarrhea, nausea, vomiting
![Page 17: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/17.jpg)
Powerpoint Templates Page 17
Risk factor
• Impaired renal function.
• Hypokalemia.
• Hypomagnesemia.
• Hypercalcemia.
• low thyroxine.
![Page 18: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/18.jpg)
Powerpoint Templates Page 18
Monitoring
• Digoxin levels are most useful if measured 4–6 hr after ingestion.
• Therapeutic serum digoxin concentration: <2ng/mL
• Toxic serum digoxin concentration: >4ng/mL
![Page 19: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/19.jpg)
Powerpoint Templates Page 19
Monitoring
• 12-lead ECG and continuous cardiac monitoring.
• Monitor electrolytes (calcium, magnesium, potassium) hourly.
![Page 20: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/20.jpg)
Powerpoint Templates Page 20
management
• Supportive Care/Decontamination:
• CAB
• Activated charcoal up to several hours postingestion.
![Page 21: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/21.jpg)
Powerpoint Templates Page 21
Specific treatment• Antidote: Digoxin Specific Antibody
Fragments (Fab)
• Indications:
• severe toxicity (ventricular, progressive bradyarrhythmias, 2nd or 3rd degree heart block).
• serum potassium >5 mEq/L .
• serum digoxin concent >4-10 ng/mL ????
![Page 22: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/22.jpg)
Powerpoint Templates Page 22
Specific treatment
• Serum digoxin concentration increases after Fab secondary to intravascular diffusion of antibody-bound, inactive digoxin.
• Adverse reactions: Allergic reaction, rebound hypokalemia, CHF (secondary to the sudden decrease in digoxin's inotropic effect).
![Page 23: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/23.jpg)
Powerpoint Templates Page 23
Treatment cont• Electrolyte disturbances (hyperkalemia):• typically self-correct after Fab treatment.
• Bradyarrhythmias: Fab is first-line therapy; consider atropine, dopamine, epinephrine, or isoproterenol for second-line therapy.
• Asystole and pulseless electrical activity (PEA) Life-threatening tachyarrhythmias Treat according to Pediatric Advanced Life Support (PALS) protocol.
![Page 24: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/24.jpg)
Powerpoint Templates Page 24
THANK YOU
![Page 25: Digoxin](https://reader036.vdocuments.pub/reader036/viewer/2022070317/556e283fd8b42a6a698b49c5/html5/thumbnails/25.jpg)
Powerpoint Templates Page 25
Management calculating the dose
• First, determine total body digoxin load (TBL):• TBL (mg) = serum digoxin level (ng/mL) × 5.6 ×
wt (kg) ÷ 1000,• OR TBL (mg) = mg digoxin ingested × 0.8• Then, calculate digoxin immune Fab dose:• Dose in number of digoxin immune Fab vials
(Digibind or DigiFab): vials = TBL ÷ 0.5• Infuse IV over 15–30 min